Considerations for regulation and evaluation of digital mental health technologies

被引:0
作者
Hopkin, Gareth [1 ]
Branson, Richard [2 ]
Campbell, Paul [2 ]
Coole, Holly [2 ]
Cooper, Sophie [1 ]
Edelmann, Francesca [2 ]
Salmon, Mark [1 ]
机构
[1] Natl Inst Hlth & Care Excellence NICE, Sci Evidence & Analyt Directorate, Level 1A,City Tower, Manchester M1 4BT, England
[2] Software Team, Healthcare Qual & Access Grp, Med & Healthcare Prod Regulatory Agcy, London, England
来源
DIGITAL HEALTH | 2024年 / 10卷
基金
英国惠康基金;
关键词
regulation; health technology assessment; evaluation; software as a medical device; SaMD; CARE;
D O I
10.1177/20552076241293313
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Digital mental health technologies (DMHTs) are becoming well established within mental health services and through direct-to-consumer models. Due to their scalable nature, DMHTs may support services to bridge the gap between demand and the available workforce, particularly where existing pathways have long delays or restricted capacity. Challenges and risks associated with DMHTs also need consideration. Regulatory and health technology assessment (HTA) agencies play a key role in ensuring the potential of DMHTs is achieved and their risks are mitigated. However, the nature of DMHTs and advances in digital technology present challenges for regulation and evaluation.In this paper, we describe eight key considerations across the regulatory and HTA pathway for DMHTs. These relate to 1) intended purpose, 2) qualification and classification, 3) risk management, 4) clinical evidence, 5) resource requirements and economic evidence, 6) post-market surveillance and life cycle assessment, 7) replicability and equity, and 8) wider responsibilities. Ensuring clarity within these considerations and addressing outstanding uncertainties is necessary to ensure that the benefits of DMHTs are unlocked, while also ensuring that people have access to high quality and safe tools.
引用
收藏
页数:7
相关论文
共 24 条
  • [1] Mental health in the digital age
    不详
    [J]. LANCET DIGITAL HEALTH, 2022, 4 (11): : E765 - E765
  • [2] [Anonymous], 2021, LANCET DIGIT HEALTH, V3, pE204, DOI 10.1016/S2589-7500(21)00045-5
  • [3] [Anonymous], 2014, Software as a Medical Device": Possible Framework for Risk Categorization and Corresponding Considerations
  • [4] Integration of digital health applications into the German healthcare system: development of "The DiGA-Care Path"
    Giebel, G. D.
    Abels, C.
    Boerchers, K.
    Kampka, B.
    Neusser, S.
    Cissarek, H. R.
    Plescher, F.
    Wasem, J.
    Blase, N.
    [J]. FRONTIERS IN HEALTH SERVICES, 2024, 4
  • [5] Identifying research priorities for digital technology in mental health care: results of the James Lind Alliance Priority Setting Partnership
    Hollis, Chris
    Sampson, Stephanie
    Simons, Lucy
    Davies, E. Bethan
    Churchill, Rachel
    Betton, Victoria
    Butler, Debbie
    Chapman, Kathy
    Easton, Katherine
    Gronlund, Toto Anne
    Kabir, Thomas
    Rawsthorne, Mat
    Rye, Elizabeth
    Tomlin, Andre
    [J]. LANCET PSYCHIATRY, 2018, 5 (10): : 845 - 854
  • [6] Hopkin G., 2024, The Lancet Digital Health
  • [7] An Introduction to Generative Artificial Intelligence in Mental Health Care: Considerations and Guidance
    King, Darlene R.
    Nanda, Guransh
    Stoddard, Joel
    Dempsey, Allison
    Hergert, Sarah
    Shore, Jay H.
    Torous, John
    [J]. CURRENT PSYCHIATRY REPORTS, 2023, 25 (12) : 839 - 846
  • [8] MHRA, 2023, GUIDANCE MANUFACTURE
  • [9] MHRA, 2023, Crafting an intended purpose in the context of software as a medical device (SaMD)
  • [10] MHRA, 2021, Guidance on software as a medical device